About Caladrius Biosciences (NASDAQ:CLBS)
Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$35.28 million
Price / Sales1.10
Price / CashN/A
Book Value$5.30 per share
Price / Book0.77
EPS (Most Recent Fiscal Year)($1.78)
Net Income$22.97 million
Return on Equity-39.28%
Return on Assets-30.61%
Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions
What is Caladrius Biosciences' stock symbol?
Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."
How were Caladrius Biosciences' earnings last quarter?
Caladrius Biosciences Inc (NASDAQ:CLBS) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.80) by $0.28. View Caladrius Biosciences' Earnings History.
When is Caladrius Biosciences' next earnings date?
What price target have analysts set for CLBS?
2 brokers have issued 12-month price objectives for Caladrius Biosciences' shares. Their predictions range from $7.00 to $12.00. On average, they expect Caladrius Biosciences' stock price to reach $9.50 in the next twelve months. View Analyst Ratings for Caladrius Biosciences.
Who are some of Caladrius Biosciences' key competitors?
Who are Caladrius Biosciences' key executives?
Caladrius Biosciences' management team includes the folowing people:
- David J. Mazzo Ph.D., Chief Executive Officer, Independent Director (Age 59)
- Joseph Talamo, Chief Financial Officer, Senior Vice President (Age 47)
- Douglas W. Losordo M.D., Chief Medical Officer (Age 58)
- Gregory B. Brown M.D., Director (Age 64)
- Richard J. Berman J.D., Independent Director (Age 75)
- Drew Bernstein CPA., , Independent Director (Age 59)
- Martyn D. Greenacre, Independent Director (Age 75)
- Steven Mark Klosk, Independent Director (Age 60)
Has Caladrius Biosciences been receiving favorable news coverage?
Media coverage about CLBS stock has trended somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Caladrius Biosciences earned a daily sentiment score of 0.11 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Caladrius Biosciences' major shareholders?
Which major investors are buying Caladrius Biosciences stock?
How do I buy shares of Caladrius Biosciences?
Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Caladrius Biosciences' stock price today?
One share of CLBS stock can currently be purchased for approximately $4.07.
How big of a company is Caladrius Biosciences?
Caladrius Biosciences has a market capitalization of $38.95 million and generates $35.28 million in revenue each year. The biotechnology company earns $22.97 million in net income (profit) each year or ($1.78) on an earnings per share basis. Caladrius Biosciences employs 22 workers across the globe.
How can I contact Caladrius Biosciences?
Caladrius Biosciences' mailing address is 106 ALLEN ROAD FOURTH FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]
MarketBeat Community Rating for Caladrius Biosciences (CLBS)MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days.